Revolutionizing Atopic Dermatitis

How should clinicians choose atopic dermatitis treatments? Harrison Nguyen, MD, discusses personalized therapy and when to escalate care.

How is drug selection evolving in atopic dermatitis? Walter Liszewski, MD, discusses personalized therapy and long-term care.

Walter Liszewski, MD, discusses how dermatologists can personalize atopic dermatitis treatment using biologics, JAK inhibitors, and topicals.

Jason Hawkes, MD, explains how new biologics and targeted therapies are advancing precision medicine and improving personalized care in atopic dermatitis.

Jason Hawkes, MD, highlights issues related to prior authorization as well as raising awareness of chronic urticaria, HS, atopic dermatitis, and other diseases.

Jason Hawkes, MD, explains how targeted therapies are advancing precision medicine and reshaping personalized care for atopic dermatitis.

Most newer nonsteroidal topical options are now approved for children as young as 2 years. Linda Stein Gold, MD, discusses adherence and misconceptions of pediatric AD.

New topical mechanisms introduce more ways to control pediatric AD without the sting, burn, or long-term steroid concerns that limit adherence, Linda Stein Gold, MD, says.

The topic of precision medicine in dermatology is explored in this segment of Bunick's interview at RAD 2026.

This interview at RAD highlights FDA-approved therapies in the atopic dermatitis treatment armamentarium.

Siegfried discusses some of the most notable highlights of her session at the RAD 2026 conference regarding clinical pearls in dermatology.

This segment of Lio's RAD Conference interview in Nashville highlights the growing number of therapeutics and an increasingly personalized approach.

Peter Lio, MD, spoke at the RAD 2026 conference about the upcoming AAD pediatric guidelines for atopic dermatitis.

Pediatric studies show dupilumab boosts height gains, eases caregiver-reported symptoms by week 2, and maintains strong skin clearance for 3 years.

This Q&A interview with Mona Shahriari, MD, highlights key atopic dermatitis tips, new developments, and themes from her session at RAD 2026.

Mona Shahriari, MD, spoke about the evolving understanding of atopic dermatitis as a systemic disease, the complexities of treatment selection, and more.

Multiple trials at RAD 2026 highlight the efficacy and safety of delgocitinib in chronic hand eczema.

RAD 2026 data indicate tralokinumab achieved significantly deeper hand eczema clearance and greater functional improvement than dupilumab in an indirect comparison.

Roflumilast cream data from RAD 2026 shed further light on the efficacy and safety across the age spectrum.

Nguyen urges clinicians to consider patient's disease presentation, comorbidities, treatment goals, and preferences when making therapeutic decisions.

At RAD 2026, Nguyen speaks on key highlights from his “Medical Crossfire” session, touching on the atopic dermatitis treatment landscape.

David Rosmarin, MD, discussed STAT6 inhibitors, ITK inhibitors, bispecifics, hand eczema, and endpoints at the RAD 2026 Conference.

Song emphasized that clinicians should think beyond the skin when managing patients with atopic dermatitis.

ARCADIA LTE data show nemolizumab maintains EASI-75 in over 90% of responders through 2 years and phase 2 pediatric data shed further light at RAD 2026.

At RAD2026, Lieberman notes advances in immunology and systemic therapies that are reshaping the link between dermatology and allergy/immunology.

A propensity-matched study shows dupilumab reduces gastrointestinal and endocrine IMID risk by 43-46% but raises psoriasis risk by 24%.

Lieberman, spoke at RAD 2026 about highlights from his session, ‘Connecting AD to Other Dermatologic Disorders and Related Comorbidities.'

RAD 2026 analyses reveal the impact of CHE on patients' lives, including its financial effects and influence on treatment decision-making.

Real-world data from the international TRACE study show 12 months of tralokinumab improved skin and quality-of-life outcomes.

Leading experts discuss managing atopic dermatitis in skin of color in a live recording from the 2025 Revolutionizing Atopic Dermatitis Conference.